New treatment for liver cancer patients

BMI The Alexandra Hospital is the first hospital in the North West to provide a new, non-surgical treatment for liver cancer.

The DEBIRI (Drug-Eluting Beads delivering Irinotecan) treatment is for patients suffering from both primary, where the disease originated in the liver or secondary liver cancer - where it travelled to the liver from another organ such as the bowel or breast.

The DEBIRI treatment is minimally invasive and treats patients who have inoperable tumours by shrinking them and making surgery possible.

The procedure involves inserting a catheter – a thin plastic tube - into an artery which supplies blood to the tumour.  The tumour is then injected with fluid containing microscopic chemotherapy beads, which directly attack the cancer.

At the same time, the beads obstruct the tumour’s blood supply, depriving it of oxygen and nutrients which prohibit its growth.  By injecting chemotherapy directly into the liver, many of the side effects can be decreased or avoided.

The DEBIRI treatment is carried out by a multi-disciplinary team at BMI The Alexandra Hospital, lead by Consultant Medical Oncologist Dr Greg Wilson, and Consultant Interventional Radiologist Dr Finn Farquharson.

Comment on this page »


Latest news

Chelsea and Westminster named the best place to work in the NHS for 2015

Nuffield Health opens doors of new Cambridge Hospital

Nuffield Health plans to open state-of-the-art diagnostic suite

New treatment for liver cancer patients
Connect with us on:

This site compiles with the HONcode standard for trustworthy health information